Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company initiated Phase 2/3 randomized trial to confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe ARDS due to COVID-19.
Product Name : Ryoncil
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable